Advertisement
Organisation › Details
Berlin Cures (Group)
Berlin Cures Holding AG, a privately-held company founded in 2014 and based in Zug, Switzerland, is establishing a new generation of treatments based on research of autoimmune diseases conducted at the renowned Charité Berlin and at the Max-Delbrueck-Center in Berlin for over a quarter of a century. The focus is to develop treatments for diseases with autoimmune pathology in which functional autoantibodies directed against G-protein-coupled receptors of different types play a significant role. With over 1000 different sub-types, the family of G-protein-receptors constitutes the largest protein super-family with the physiological ability to sense molecules outside the cell. Berlin Cures holds the IP for a platform of aptamers that bind to and neutralize these functional autoantibodies, which play an important role in the pathophysiology of several autoimmune-diseases. Recent studies involving heart failure, pulmonary hypertension, chronic fatigue syndrome, pre-eclampsia and a significant number of other diseases have shown that these functional autoantibodies play a highly underestimated role in disease development and sustenance. Neutralizing these autoantibodies can lead to substantial improvements in treatment. *
Start | 2014-09-01 splitoff | |
Predecessor | Charité – Universitätsmedizin Berlin (Charité University Hospital) | |
Industry | aptamer drug | |
Industry 2 | BC007 (Berlin Cures) | |
Person | Müller, Johannes (Berlin Cures 201409– CEO + Co-founder) | |
Region | Berlin | |
Country | Germany | |
Street | 59-61 Knesebeckstr. | |
City | 10719 Berlin | |
Tel | +49-30-88017160 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Berlin Cures Holding AG. (8/22/18). "Press Release: Berlin Cures Announces Successful Completion of Phase 1 Study of BC 007 for the Treatment of Cardiomyopathy". Zug. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Berlin Cures (Group)
- [1] Berlin Cures Holding AG. (8/22/18). "Press Release: Berlin Cures Announces Successful Completion of Phase 1 Study of BC 007 for the Treatment of Cardiomyopathy". Zug....
- [2] Berlin Cures Holding AG. (2/26/18). "Press Release: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study". Zug & Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top